



Investment and Exit

Eye-care chain Dr Agarwal's raises debt funding from Britain's CDC

18th Dec 2019. VCCircle

Dr Agarwal's Health Care Ltd on Wednesday said it has raised Rs 215 crore (\$30.3 million) in debt from British development finance institution (DFI) CDC Group Plc -- the transaction bumping up the number of fundraisings in India's eye-care sector to six deals... [more](#)

Fund Raising

Trivitron Healthcare eyes Rs. 1,000 crore revenue for 2020-21; likely to go for IPO

31st Dec 2019. Pharma Biz

The company is planning to go for a new private equity round of funding in the next financial year beginning April 2020... [more](#)

Merger and Acquisition

Cipla acquires India trademark rights for anti-diabetic drug from Novartis

16th Dec 2019. VCCircle

Indian pharmaceutical major Cipla Ltd has acquired the brand name and trademark rights for Vysov and Vysov M (Vildagliptin and Metformin) of the anti-diabetic drug Vildagliptin for the local market from Novartis AG... [more](#)

Eurolife Healthcare acquires intravenous infusion business of Teva, Hungary

24th Dec 2019. ET Health World

Drug firm Eurolife Healthcare on Tuesday said it has completed the acquisition of intravenous (IV) infusion business of Teva Pharmaceutical Industries, Hungary.... [more](#)

SPARC signs pact with Bioprojet to acquire exclusive rights for drug to treat auto-immune diseases

19th Dec 2019. ET Health World

Sun Pharma Advanced Research Company (SPARC) on Thursday said that it has entered a pact with Bioprojet SCR (Bioprojet) to acquire exclusive rights for investigational medicinal product SCD-044, SCD-044 which is a novel investigational oral product, under development for the treatment of auto-immune diseases... [more](#)

Joint Venture

Guyana seeks JVs with Indian cos for manufacturing intravenous fluid in Guyana and supplying to CARICOM countries

16th Dec 2019. Pharma Biz

Guyana, a country on the northern mainland of South America, has sought Joint Ventures with Indian pharmaceutical companies for manufacturing intravenous fluid in Guyana and supplying to CARICOM countries... [more](#)

Pharma

FDA approves first generics of Eliquis

24th Dec 2019. The Pharma Letter

The US Food and Drug Administration has approved two applications for the first generics of Bristol... [more](#)

Glenmark Pharma's Ryaltris gets first approval

20th Dec 2019. [The Pharma Letter](#)

Indian drugmaker Glenmark Pharmaceuticals says that partner Seqirus has received marketing approval... [more](#)

Lupin gets USFDA nod to market skin ointment

20th Dec 2019. [Economic Times](#)

Pharma major Lupin on Friday said it has received the USFDA's approval to market its Betamethasone Dipropionate ointment (augmented), in the American market... [more](#)

Belgium invites Indian pharma & biotech cos to invest and utilise huge opportunities offered by the country

16th Dec 2019. [Pharma Biz](#)

Belgium, the global pharma and life sciences hub in Europe, has invited Indian pharmaceutical and biotechnology companies to invest in Belgium and utilise the huge investment opportunities offered by the country... [more](#)

Mankind Pharma signs up with Glenmark Pharmaceuticals for co-marketing of Remogliflozin Etabonate in India

23rd Dec 2019. [ET Health World](#)

Mankind Pharmaceuticals Ltd. and Glenmark Pharmaceuticals Ltd. today inked a sub-licensing agreement to co-market sodium glucose co-transporter-2 (SGLT2) inhibitor, Remogliflozin Etabonate (Remogliflozin) in India... [more](#)

Glenmark gets approval from Australian regulator to commercialise Ryaltris

20th Dec 2019. [ET Health World](#)

Drug maker Glenmark Pharmaceuticals on Friday said that it has received approval from Australian regulator Therapeutic Goods Administration (TGA) to commercialise Ryaltris in Australia through its partner Seqirus.... [more](#)

Lupin's partner Concord gets USFDA nod to market Myfortic tablet

19th Dec 2019. [ET Health World](#)

Pharma major Lupin on Thursday said its alliance partner Concord Biotech has received approval from the US health regulator for generic immunosuppressive Mycophenolic acid delayed-release tablets.... [more](#)

Nectar Biopharma rolls out generic diabetes drug

26th Dec 2019. [Bio Spectrum](#)

In what comes as good news for over 72 million diabetics in India, more affordable diabetic care is finally here with Nectar Biopharma, a leading company specialising in generic formulations, launching the generic version of vildagliptin... [more](#)

Lupin launches Doxercalciferol Injection

19th Dec 2019. [Bio Spectrum](#)

Lupin announced the launch of Doxercalciferol Injection, 4 mcg/2 mL (2 mcg/mL) Multi-dose Vials, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier... [more](#)

Dr. Reddys Labs launches generic Nitropress injection

31st Dec 2019. [Pharma Biz](#)

Dr. Reddys Laboratories Ltd announced the launch of the US Food and Drug Administration (FDA) approved sodium nitroprusside injection, 50 mg/2 mL (25 mg/mL) single-dose vial, the therapeutic generic equivalent of Nitropress (sodium nitroprusside) injection, 50 mg/2mL vial.... [more](#)

Chemical

India starts probe into alleged dumping of chemical from China

24th Dec 2019. [Economic Times](#)

India has initiated a probe into alleged dumping of a chemical, used in dye and pharma industry, from China following a complaint by a domestic company... [more](#)

HealthCare

Piramal enterprises looks to sell 20% equity in healthcare business

18th Dec 2019. [Economic Times](#)

Piramal Enterprises Ltd. has put up 20% equity in its healthcare vertical for sale, seeking to expand the business.... [more](#)

Piramal Swasthya join hands with Rockefeller Foundation to strengthen India's healthcare scenario

17th Dec 2019. [Economic Times](#)

Piramal Swasthya Management and Research Institute, the primary healthcare initiative of Piramal Foundation joined hands with New-York based Rockefeller Foundation to strengthen maternal and child health in the aspirational districts of India thereby improving the country's health index... [more](#)

Zydus Cadila in talks to sell two units for Rs 1,200 crore

27th Dec 2019. [Economic Times](#)

Zydus Cadila, a group company of listed drug-maker Cadila Healthcare, is in preliminary talks with several strategic and private equity investors to sell two of its divisions - anti-infectives and gynaecology - for about Rs 1,000-1,200 crore... [more](#)

Paras Healthcare, PSU Heavy Engineering Corporation (HEC) join hands to establish a presence in Jharkhand

27th Dec 2019. [ET Health World](#)

Undoubtedly, there have been several efforts to expand presence in Tier II and Tier III cities of northern India, and as a part of these efforts, leading healthcare provider Paras Healthcare has tied up with PSU Heavy Engineering Corporation (HEC) to establish and operate a 300-bed multi-speciality hospital in Ranchi... [more](#)

MIP enters India market

16th Dec 2019. [Express Healthcare](#)

MIP aims to power the healthcare segment with effective, affordable and quality healthcare textile products... [more](#)

Hospital

Apollo Hospitals launch robot-assisted cardiac surgery unit

19th Dec 2019. [Economic Times](#)

Apollo Hospitals Bangalore on Thursday announced the launch of the first dedicated Robot-Assisted Cardiac Surgery Unit in India... [more](#)

Madhavbaug plans to open 800 cardiac care clinics and hospitals by 2025

21st Dec 2019. [Pharma Biz](#)

Madhavbaug, one of the leading chains of cardiac care clinics and hospitals is planning to open 800 clinics and 10 hospitals by 2025. It currently has 216 clinics pan India.... [more](#)

Care Hospitals to add 800 beds across India by 2021

30th Dec 2019. [Express Healthcare](#)

Care Hospitals, part of Dubai-headquartered Evercare Group, is looking to add 800 beds in its portfolio across India by 2021... [more](#)

Biotech

Panacea Biotec bags orders worth USD 24 mn from UN agencies

19th Dec 2019. [Economic Times](#)

Panacea Biotec on Thursday said it has bagged orders worth USD 24.32 million (over Rs 170 crore) from UN agencies, including Unicef, for the supply of Pentavalent vaccine... [more](#)

First FDA-approved vaccine for the prevention of Ebola virus disease

20th Dec 2019. [Pharma Tutor](#)

The U.S. Food and Drug Administration announced the approval of Ervebo, the first FDA-approved vaccine for the prevention of Ebola virus disease (EVD)... [more](#)

Global News

Astellas strengthens I-O pipeline with buy of Xyphos

27th Dec 2019. [The Pharma Letter](#)

Japanese drug major Astellas Pharma yesterday announced that it has acquired privately-held US biotech... [more](#)

Towa Pharma acquiring Esteve's generics business

23rd Dec 2019. [The Pharma Letter](#)

Japan's Towa Pharmaceutical today announced that it will acquire 100% ownership of Pensa... [more](#)

Truffle Capital sniffs out € 250M for its BioMedTech startup fund

19th Dec 2019. [Fierce Biotech](#)

Parisian venture firm Truffle Capital has secured € 250 million (\$278 million) for its biotech and medtech fund, with plans to seed about a dozen new healthcare-focused companies, located mainly in France... [more](#)

Turnstone teams up with Takeda in \$900M deal to work on biotech's oncolytic drug

19th Dec 2019. [Fierce Biotech](#)

The pact, which has a substantial \$120 million upfront in cash, sees Takeda gain an exclusive worldwide license to co-develop and co-commercialize Turnstone's leading (but still early-stage) oncolytic candidate RIVAL-01.... [more](#)

Cellestia Biotech AG successfully closes Series B financing round, raising a total of CHF 20 million

17th Dec 2019. Biospaces

Cellestia Biotech AG today announced the closing of a CHF 20 million Series B financing round. The new funds will be added to the previous, including CHF 8 million Seed financing... [more](#)

Janssen completes acquisition of investigational compound bermekimab from XBiotech for US\$ 750 million

31st Dec 2019. Pharma Biz

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the completion of the acquisition of all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees, from XBiotech Inc., for US\$ 750 million... [more](#)

Best Regards



Monal capital
Believe in values

Pooja Shah

Head-Research

Monal Capital (P) Limited

Tel.: +91-22-4976 1501 | 4976 1601 | 47081900 Mobile: +91 845480 7250 | [Email: pooja@monalcapital.com](mailto:pooja@monalcapital.com)

114, The Summit business bay, W.E. Highway Metro station, Opp.PVR, Off Andheri Kurla Road, Andheri (E) , Mumbai : 400 093 India,

[Website: www.monalcapital.com](http://www.monalcapital.com)

[Investment Banking - Debt Syndication](#) | [Corporate Finance](#) | [Bonds](#) | [Equity](#) | [Infrastructure](#) | [Real Estate](#) | [M&A](#) | [Stress Asset Solutions](#) | [Startup & VC Advisory](#)

Disclaimer: Information gathered & material used in this document is believed to be from reliable sources. Monal Capital however does not warrant the accuracy, reasonableness and/or completeness of any information. Monal Capital and any of its officer's directors, personnel and employees, shall not liable for any loss, damage of any nature, including but not limited to direct, indirect, punitive, special, exemplary, consequential, as also any loss of profit in any way arising from the use of this material in any manner